Real-World Safety Outcomes of Intravitreal Ranibizumab Biosimilar (Razumab) Therapy for Chorioretinal Diseases

INTRODUCTION: To assess the safety profile of the intravitreal ranibizumab biosimilar molecule, Razumab(®) (Intas Pharmaceuticals, Ahmedabad, India) in chorioretinal disorders under real-world conditions. METHODS: This was a multicenter, retrospective chart review which included patients from 15 cen...

Descripción completa

Detalles Bibliográficos
Autores principales: Chakraborty, Debdulal, Stewart, Michael W., Sheth, Jay U., Sinha, Tushar K., Boral, Subhendu, Das, Arnab, Mondal, Soumen, Mukherjee, Angshuman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079600/
https://www.ncbi.nlm.nih.gov/pubmed/33864599
http://dx.doi.org/10.1007/s40123-021-00345-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079600/
https://www.ncbi.nlm.nih.gov/pubmed/33864599
http://dx.doi.org/10.1007/s40123-021-00345-2

Ejemplares similares